Valeria Lungu

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
PURPOSE In order to optimize radioimmunotherapy (RIT) as a cancer treatment modality, it is necessary to select the appropriate radionuclide and the biomolecule carrier. We have developed the radiolabeling with (188)Re (beta emitter) of anti-carcinoembryonic antigen (CEA) monoclonal antibody (Mab) for targeting CEA-producing tumors. MATERIALS AND METHODS(More)
Neurotensin (NT) is a peptide with biological affinity to neurotensin receptors (NTR), while SR48692 is a non-peptide molecule with competitive/inhibitory activity to the same receptors. This paper aims to bring a scientific contribution to elucidate the paradigm concerning the capture of NT agonist or antagonist (SR48692) by tumor cells, depending on the(More)
  • 1